NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System

"This milestone further validates the intended benefits of our OneRF platform," said Dave Rosa, CEO of NeuroOne. "Our next step is to leverage the technology for other applications, including our OneRF Trigeminal Nerve Ablation System to treat facial pain, for which we filed a 510(k) submission to the FDA in April 2025." "Around this time last year, I was having multiple seizures every day, which interfered with so many things in my life," stated Clara. "However, since the procedure, I completely stopped ha ...